Inventor
Yuanyuan JIANG
Inventor
CN
Overview
Patents· 17 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Kprimary
A61KPreparations for medical, dental or toiletry purposes25%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations25%
C07DHeterocyclic compounds22%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium11%
C12NMicroorganisms or enzymes4%
G06FElectric digital data processing4%
G06TImage data processing or generation, in general4%
G09BEducational or demonstration appliances4%
LOC022%
PatentTitleYear
12,582,653Method for treating idiopathic pulmonary fibrosis202612,544,3822, 4, 6-tri-substituted pyrimidine compound as ATR kinase inhibitor202612,509,479P2X3 and/or P2X2/3 receptor antagonist, pharmaceutical composition comprising same, and use thereof202512,485,108Method for treating fatty liver disease and/or steatohepatitis202512,410,192Compound for inhibiting and inducing degradation of EGFR kinase202512,398,118Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and use thereof202512,180,243Receptor inhibitor, pharmaceutical composition comprising same, and use thereof202412,175,882Hands-on laboratory and demonstration equipment with a hybrid virtual/augmented environment, along with their methods of use202411,939,578Double-stranded RNA molecule targeting CKIP-1 and use thereof202411,919,918P2X3 andor P2X2/3 receptor antagonist, pharmaceutical composition comprising same, and use thereof202411,905,274Receptor inhibitors, pharmaceutical compositions comprising the same and use thereof2024D0997494Skirt202311,694,575Hands-on laboratory and demonstration equipment with a hybrid virtual/augmented environment, along with their methods of use202311,453,690Receptor inhibitor, pharmaceutical composition comprising same, and use thereof202211,414,444P2X3 and/or P2X2/3 receptor antagonist, pharmaceutical composition comprising same, and use thereof202211,390,609Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and preparation method and use thereof202211,155,819Double-stranded RNA molecule targeting CKIP-1 and use thereof2021Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2021–2026Patents assigned to BEIJING TIDE PHARMACEUTICAL CO LTD (14)· patent assignee history
2021–2026Based in CN· patent location history
2023–2024Patents assigned to THE TRUSTEES OF THE CALIFORNIA STATE UNIV (2)· patent assignee history
2023Patents assigned to JIANG YUANYUAN (1)· patent assignee history
2023Patents assigned to The California State University—San Marcos (1)· patent assignee history
2023–2024Based in US· patent location history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| BEIJING TIDE PHARMACEUTICAL CO LTD | 14 | 2021–2026 |
| THE TRUSTEES OF THE CALIFORNIA STATE UNIV | 2 | 2023–2024 |
| JIANG YUANYUANself | 1 | 2023 |
| The California State University—San Marcos | 1 | 2023 |
Locations
| Location | Patents | Span |
|---|---|---|
| CN | 15 | 2021–2026 |
| US | 2 | 2023–2024 |